Patient-derived organoids for therapy personalization in inflammatory bowel diseases

doi:10.3748/wjg.v28.i24.2636

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6987)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

396

WORD

HTML

4234

Figures (1-1)

284

Tables (1-3)

305

Sum=5282

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

209

Download

303

Sum=512

Publishing Process of This Article

Item

Count

Browse

379

Download

814

Sum=1193

Jun 28, 2022 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Jun 28, 2022; 28(24): 2636-2653
Published online Jun 28, 2022. doi: 10.3748/wjg.v28.i24.2636

Table 2 Novel potential molecular targets identified using intestinal organoids

Potential molecular targets	Effect	Species	Ref.
LRH-1	Improved resistance to pro-inflammatory mediators and induced mucosal healing	Humanized mouse (Lrh-1^-/-LRH-1^+/+) and Human	[94]
PXR	Reduced NF-kB activity	Human (IBD patients)	[97]
IL-22-pSTAT3 SP	Restored tissue damage and intestinal homeostasis	Mouse (ATF3^-/-)	[98]
TGF-β SP	Arrested inflammatory signals	Mouse	[104]
SIRT2	Regulated Wnt/β-catenin SP	Mouse (Sirt2^–/–)	[105]

ATF3: Activating transcription factor 3; IBD: Inflammatory bowel disease; IL: Interleukin; LRH-1: Liver receptor homolog 1; NF-kB: Nuclear factor-kappa B; PXR: Pregnane X receptor; SIRT2: Human sirtuin protein 2; SP: Signaling pathway; STAT: Signal transducer and activator of transcription; TGF-β: Transforming growth factor Β.

Citation: Lucafò M, Muzzo A, Marcuzzi M, Giorio L, Decorti G, Stocco G. Patient-derived organoids for therapy personalization in inflammatory bowel diseases. World J Gastroenterol 2022; 28(24): 2636-2653
URL: https://www.wjgnet.com/1007-9327/full/v28/i24/2636.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i24.2636